These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19342465)

  • 21. Study design: statistical and methodologic considerations.
    Rubenfeld GD
    Respir Care; 1995 Sep; 40(9):980-6. PubMed ID: 10152244
    [No Abstract]   [Full Text] [Related]  

  • 22. Challenges of cluster randomized trials.
    Campbell MJ
    J Comp Eff Res; 2014 May; 3(3):271-81. PubMed ID: 24969154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early viewing of noninferiority trials in progress.
    Dignam JJ
    J Clin Oncol; 2005 Aug; 23(24):5461-3. PubMed ID: 16027438
    [No Abstract]   [Full Text] [Related]  

  • 24. Distinguishing Between Efficacy and Real-World Effectiveness: The Case for Thinking Beyond Classic Randomized Controlled Trial Design.
    Sites BD; Masaracchia MM; Davis M
    Reg Anesth Pain Med; 2017; 42(2):131-132. PubMed ID: 28207640
    [No Abstract]   [Full Text] [Related]  

  • 25. Meta-analysis of clinical trials with early stopping: an investigation of potential bias.
    Schou IM; Marschner IC
    Stat Med; 2013 Dec; 32(28):4859-74. PubMed ID: 23824994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized two-stage Phase II clinical trial designs based on Barnard's exact test.
    Shan G; Ma C; Hutson AD; Wilding GE
    J Biopharm Stat; 2013; 23(5):1081-90. PubMed ID: 23957517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equipoise, design bias and randomized controlled trials: the elusive ethics of new drugs--a comment.
    Schimetta W; Poelz G; Poelz W; Haring HP; Aichner F
    Arthritis Res Ther; 2004 Nov; 7(1):E2. PubMed ID: 15642128
    [No Abstract]   [Full Text] [Related]  

  • 28. Korn and Freidlin's misunderstanding of the null hypothesis significance testing procedure.
    Trafimow D; Rice S
    Am J Bioeth; 2011 Mar; 11(3):15-6. PubMed ID: 21400377
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Counterpoint: epidemiology to guide decision-making: moving away from practice-free research.
    Hernán MA
    Am J Epidemiol; 2015 Nov; 182(10):834-9. PubMed ID: 26507306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early stopping of randomized clinical trials for overt efficacy is problematic.
    Bassler D; Montori VM; Briel M; Glasziou P; Guyatt G
    J Clin Epidemiol; 2008 Mar; 61(3):241-6. PubMed ID: 18226746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deconstructing evidence in orthodontics: making sense of systematic reviews, randomized clinical trials, and meta-analyses.
    Rinchuse DJ; Rinchuse DJ; Kandasamy S; Ackerman MB
    World J Orthod; 2008; 9(2):167-76. PubMed ID: 18575311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early stopping rules--clinical perspectives and ethical considerations.
    Baum M; Houghton J; Abrams K
    Stat Med; 1994 Jul 15-30; 13(13-14):1459-69; discussion 1471-2. PubMed ID: 7973225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ALS issues in clinical trials. Missing data.
    Thompson JL; Levy G
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():48-51. PubMed ID: 15512872
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical trials--multiple treatments, multiple end points, and multiple lessons.
    Lauer MS; Topol EJ
    JAMA; 2003 May; 289(19):2575-7. PubMed ID: 12759328
    [No Abstract]   [Full Text] [Related]  

  • 37. [Statistical significance or clinical relevance?].
    Vanhoutte EK; Faber CG; Merkies IS
    Ned Tijdschr Geneeskd; 2010; 154():A2516. PubMed ID: 21176250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Jan; 99(2):284-7. PubMed ID: 17223435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust estimating functions and bias correction for longitudinal data analysis.
    Wang YG; Lin X; Zhu M
    Biometrics; 2005 Sep; 61(3):684-91. PubMed ID: 16135019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of censoring on progression free survival: oncologist discretion advised.
    Prasad V; Bilal U
    Eur J Cancer; 2015 Nov; 51(16):2269-71. PubMed ID: 26259493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.